NASDAQ:INTS
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. reported net income of −$11.6M in fiscal 2025. The diluted share count rose 143.8%.Summary generated from Intensity Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−156.9%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+143.8%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a |
| Operating income | −8 | −8 | −17 | −12 |
| Net income | −8 | −11 | −16 | −12 |
| Free cash flow | n/a | n/a | n/a | n/a |
Recent filings
- 8-KResults of operations and financial condition
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 4Insider transaction report
Jul 20, 2026 - 4Insider transaction report
Jul 20, 2026 - 8-KResults of a shareholder vote
Jun 16, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - DEF 14AProxy statement
Apr 30, 2026